Coagulation and the xenograft endothelium

Xenotransplantation

Volumn 14, Issue 1, 2007, Pages 7-12

  Cowan, Peter J ^a,b  

^a Immunology Research Centre   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Coagulation; Endothelium; Thrombosis; Xenotransplantation

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBIN; HEPARIN;

BLOOD CLOTTING; BLOOD CLOTTING DISORDER; DISSEMINATED INTRAVASCULAR CLOTTING; DNA MODIFICATION; ENDOTHELIUM; GENETIC INCOMPATIBILITY; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; THROMBOSIS; XENOGRAFT; XENOTRANSPLANTATION;

ANIMALS; BLOOD COAGULATION; ENDOTHELIUM; HUMANS; THROMBOSIS; TISSUE DONORS; TRANSPLANTATION, HETEROLOGOUS;

EID: 33845994431     PISSN: 0908665X     EISSN: 13993089     Source Type: Journal    
DOI: 10.1111/j.1399-3089.2006.00368.x     Document Type: Review

References (30)

1. TSENG YL, KUWAKI K, DOR FJ et al. α1,3-Galactosyltransferase gene-knockout pig heart transplantation in baboons with survival approaching 6 months. Transplantation 2005; 80: 1493-1500.
2. CHEN D, DORLING A. Microcoagulation processes after xenotransplantation. Curr Opin Organ Transplant 2005; 10: 240-245.
3. LWALEED BA, BASS PS. Tissue factor pathway inhibitor: structure, biology and involvement in disease. J Pathol 2006; 208: 327-339.
4. PIRO O, BROZE GJ. Role for the Kunitz-3 domain of tissue factor pathway inhibitor-α in cell surface binding. Circulation 2004; 110: 3567-3572.
5. MARONEY SA, CUNNINGHAM AC, FERREL J et al. A GPI-anchored co-receptor for tissue factor pathway inhibitor controls its intracellular trafficking and cell surface expression. J Thromb Haemost 2006; 4: 1114-1124.
6. ZHANG J, PIRO O, LU L, BROZE GJ. Glycosyl phosphatidylinositol anchorage of tissue factor pathway inhibitor. Circulation 2003; 108: 623-627.
7. PIRO O, BROZE GJ. Comparison of cell-surface TFPIα and β. J Thromb Haemost 2005; 3: 2677-2683.
8. PIKE RN, BUCKLE AM, LE BONNIEC BF, CHURCH FC. Control of the coagulation system by serpins. Getting by with a little help from glycosaminoglycans. FEBS J 2005; 272: 4842-4851.
9. ESMON CT. The protein C pathway. Chest 2003; 124: 26S-32S.
10. AIRD WC. Spatial and temporal dynamics of the endothelium. J Thromb Haemost 2005; 3: 1392-1406.
11. BANZ Y, RIEBEN R. Endothelial cell protection in xenotransplantation: looking after a key player in rejection. Xenotransplantation 2006; 13: 19-30.
12. GHANEKAR A, MENDICINO M, LIU H et al. Endothelial induction of Fgl2 contributes to thrombosis during acute vascular xenograft rejection. J Immunol 2004; 172: 5693-5701.
13. ROBSON SC, KACZMAREK E, SIEGEL JB et al. Loss of ATP diphosphohydrolase activity with endothelial cell activation. J Exp Med 1997; 185: 153-163.
14. KHALPEY Z, YUEN AH, KALSI KK et al. Loss of ecto-5′ nucleotidase from porcine endothelial cells after exposure to human blood: implications for xenotransplantation. Biochim Biophys Acta 2005; 1741: 191-198.
15. GLASER CB, MORSER J, CLARKE JH et al. Oxidation of a specific methionine in thrombomodulin by activated neutrophil products blocks cofactor activity. A potential rapid mechanism for modulation of coagulation. J Clin Invest 1992; 90: 2565-2573.
16. KOPP CW, SIEGEL JB, HANCOCK WW et al. Effect of porcine endothelial tissue factor pathway inhibitor on human coagulation factors. Transplantation 1997; 63: 749-758.
17. KOPP CW, ROBSON SC, SIEGEL JB et al. Regulation of monocyte tissue factor activity by allogeneic and xenogeneic endothelial cells. Thromb Haemost 1998; 79: 529-538.
18. SIEGEL JB, GREY ST, LESNIKOSKI B-A et al. Xenogeneic endothelial cells activate human prothrombin. Transplantation 1997; 64: 888-896.
19. KOPP CW, GREY ST, SIEGEL JB et al. Expression of human thrombomodulin cofactor activity in porcine endothelial cells. Transplantation 1998; 66: 244-251.
20. LAWSON JH, DANIELS LJ, PLATT JL. The evaluation of thrombomodulin activity in porcine to human xenotransplantation. Transplant Proc 1997; 29: 884-885.
21. SHIRAISHI M, OSHIRO T, TAIRA K et al. Improved hepatic microcirculation by human soluble urinary thrombomodulin in the xeno-perfused porcine liver. Transplantation 2001; 71: 1046-1050.
22. COWAN P, ROUSSEL JC, MORAN C, D'APICE A. Characterization of pig thrombomodulin and its interaction with the human protein C anticoagulant pathway. Xenotransplantation 2005; 12: 382.
23. COWAN PJ, AMINIAN A, BARLOW H et al. Protective effects of recombinant human antithrombin III in pig-to-primate renal xenotransplantation. Am J Transplant 2002; 2: 520-525.
24. KUWAKI K, KNOSALLA C, DOR FJ et al. Suppression of natural and elicited antibodies in pig-to-baboon heart transplantation using a human anti-human CD154 mAb-based regimen. Am J Transplant 2004; 4: 363-372.
25. COZZI E, SIMIONI P, BOLDRIN M et al. Effects of long-term administration of high-dose recombinant human antithrombin in immunosuppressed primate recipients of porcine xenografts. Transplantation 2005; 80: 1501-1510.
26. BYRNE GW, SCHIRMER JM, FASS DN et al. Warfarin or low-molecular-weight heparin therapy does not prolong pig-to-primate cardiac xenograft function. Am J Transplant 2005; 5: 1011-1020.
27. DWYER KM, ROBSON SC, NANDURKAR HH et al. Thromboregulatory manifestations in human CD39 transgenic mice and the implications for thrombotic disease and transplantation. J Clin Invest 2004; 113: 1440-1446.
28. DWYER KM, MYSORE TB, CRIKIS S et al. The transgenic expression of human CD39 on murine islets inhibits clotting of human blood. Transplantation 2006; 82: 428-432.
29. CHEN D, WEBER M, MCVEY JH et al. Complete inhibition of acute humoral rejection using regulated expression of membrane-tethered anticoagulants on xenograft endothelium. Am J Transplant 2004; 4: 1958-1963.
30. MENDICINO M, LIU M, GHANEKAR A et al. Targeted deletion of Fgl-2/fibroleukin in the donor modulates immunologic response and acute vascular rejection in cardiac xenografts. Circulation 2005; 112: 248-256.